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Bovine chymosin is an important milk-clotting agent used in the manufacturing of cheeses. Currently, the
production of recombinant proteins by genetically modiﬁed organisms is widespread, leading to greatly reduced costs.
Lactococcus (L.) lactis, the model lactic acid bacterium, was considered a good candidate for heterologous chymosin
production for the following reasons: (1) it is considered to be a GRAS (generally regarded as safe) microorganism, (2)
only one protease is present on its surface, (3) it can secrete proteins of different sizes, and (4) it allows for the direct
production of protein in fermented food products. Thus, three genetically modiﬁed L. lactis strains were constructed to
produce and target the three different forms of bovine chymosin, prochymosin B, chymosin A and chymosin B to the
extracellular medium. Although all three proteins were stably produced in L. lactis, none of the forms were detected in
the extracellular medium or showed clotting activity in milk. Our hypothesis is that this secretion deﬁciency and lack of
clotting activity can be explained by the recombinant protein being attached to the cell envelope. Thus, the
development of other strategies is necessary to achieve both production and targeting of chymosin in L. lactis, which
could facilitate the downstream processing and recovery of this industrially important protein.
Introduction
Bovine chymosin (EC 3.4.23.4) is the major enzyme
responsible for the coagulation of milk in the abomasum of
suckling calves.1 This aspartyl proteinase is secreted as a 365
amino acid inactive precursor prochymosin, which can be con-
verted into active chymosin in the acidic environment of the
stomach by proteolytic removal of a 42 amino acid propeptide
at the N-terminus. Chymosin recognizes and partially hydro-
lyzes k-casein, a protein that consists of a hydrophobic and
hydrophilic portion and is located on the surface of caseins
that are present in milk. Chymosin releases a hydrophilic k-
casein glycopeptide, and the insoluble para-k-casein peptide
aggregates with other caseins to form an insoluble clot via a
Ca2C dependent process.2,3
Chymosin is one of the most important enzymes in the
cheese-making process due to its high specificity for casein.4,5
Commercial preparations of calf rennet contain two forms of
chymosin, denominated chymosin A and B. Chymosin A slightly
exceeds chymosin B in proteolytic activity, whereas chymosin B
is more stable at low pH. Chymosin A differs from chymosin B
in only one amino acid; the A form has an aspartic acid residue at
position 286, whereas the B form has a glycine residue at this
position.6
The expansion of cheese production is limited by the reduc-
tion of chymosin rennet in livestock slaughter, requiring the
development of alternative chymosin sources. Using genetic engi-
neering techniques, recombinant chymosin has been expressed in
several microbes, including Escherichia coli, Bacillus subtilis, and
Kluyveromyces lactis.4,7-9 Microbiologically produced recombi-
nant chymosin costs less and is obtained with high purity and in
abundant quantities.10 Several biotechnology companies produce
recombinant chymosin for commercial use in the cheese-making
process.4 Genetically modified organism (GMO)-based rennet is
now used in 80% of global cheese production.10
Lactic acid bacteria (LAB) are a group of gram-positive, non-
sporulating bacteria that produce lactic acid, a common meta-
bolic end product from the fermentation of carbohydrates. LAB
are widely used in the food industry for production and preser-
vation of fermented products. These bacteria are also considered
to be GRAS (generally regarded as safe) organisms.11 Lactococcus
(L.) lactis, the model LAB, is a good candidate for heterologous
protein production, especially for recombinant protein secre-
tion. Through a Sec-dependant pathway, L. lactis is able to
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secrete recombinant proteins of different sizes. Secretion of these
proteins leads to the direct production of several proteins in fer-
mented food products facilitating the interaction of the secreted
proteins (enzymes or antigens) and their environment (the food
products themselves or the digestive tract of animals that con-
sume these engineered bacteria).12 Due to this, it would be
advantageous to use lactococci as chymosin producers because
no foreign components of the host would be added to the
cheese vat.
For these reasons, genetically modified L. lactis strains were
constructed for the production and targeting, to the extracellular
medium, of three derivate forms of the bovine chymosin gene
and evaluated for their milk-clotting potential.
Results
Cloning of synthetic prochymosin B gene using the XIES
system
Considering that calf chymosin is an important enzyme
involved in the process of milk coagulation and commonly used
in cheese manufacturing, the principal aim of the present work
was to evaluate the production and secretion of active chymosin
by L. lactis strains. For this purpose, we constructed three differ-
ent recombinant L. lactis strains using the xylose-inducible
expression system (XIES),13 which targets the secretion of the
protein of interest to the extracellular medium. Three derivates
of the calf chymosin cDNA gene, prochymosin B, chymosin A,
and chymosin B, were used to construct the recombinant lactoc-
coci strains.
The prochymosin B ORF (Bos taurus; NM_180994.1), with
all codons optimized for its expression in L. lactis, was commer-
cially synthesized and cloned into the pBluescript II SK (C/¡)
vector resulting in the pBSIISK:prochyB vector (Epoch Biolabs
Inc). The prochymosin B gene sequence was used as a template
to obtain the chymosin A and B ORFs (Fig. 1). The nucleotide
sequences of these genes were cloned into the pXYSEC expres-
sion vector after the ribosome binding site (RBS) and the DNA
sequence encoding a signal peptide (SP) of the major lactococcal
secreted protein Usp45 (RBSusp45 and SPusp45). Usp45 is one of
the few secreted proteins of L. lactis and is the only secreted pro-
tein expressed in sufficient quantities to be detected on protein
gels stained with Coomassie Blue.14 The pXYSEC plasmid was
successfully used to clone the prochymosin B gene in frame with
the signal peptide. To obtain the plasmid that would target the
prochymosin protein to the L. lactis extracellular medium (pXY-
SEC:prochyB), the prochymosin gene was PCR amplified from
pBSIISK:prochyB (Table 1) using primers prochyB F and pro-
chyB R (Table 2). The PCR product was digested with the corre-
sponding restriction enzymes, purified and cloned into the
purified NsiI-EcoRV-cut pXYSEC expression vector. The con-
struction of the recombinant pXYSEC:prochyB plasmid
(Table 1; Fig. 2A) was confirmed via enzymatic digestion and
DNA sequencing. The confirmed plasmid was first transformed
in E. coli TOP10 cells and then transferred into L. lactis
NCDO2118 (wild type) cells, which were used as the cloning
host, resulting in the LL pXIES:prochyB recombinant strain. This
is the first time that L. lactis NCDO2118 has been used to
express prochymosin.
L. lactis is able to produce a stable form of synthetic
prochymosin B but does not secret it
To evaluate whether the LL pXIES:prochyB strain was able to
produce the synthetic prochymosin B and target it outside the
cell, western blotting analysis was performed using the proteins
extracted from the cell (C) and supernatant (S) fractions of
induced and non-induced LL pXIES:prochyB and L. lactis
NCDO2118 cultures. Analysis of induced LL pXIES:prochyB
samples revealed a 43 kg.mol¡1 polypeptide in the C fraction,
which corresponds to prochymosin B fused to the signal peptide
of the Usp45 protein (SPUsp45::prochyB). These polypeptides
were not detected in control extracts (Fig. 2B). No proteins were
observed in the S fraction (data not shown).
Because the constructed LL pXIES:prochyB strain was not able
to target the synthetic prochymosin B to the extracellular
medium, we decided to investigate the lack of chymosin secretion
by LL pXIES:prochyB. Therefore, to determine whether the pro-
tein was being retained in the cell wall or in the cytoplasm of the
bacteria, the induced L. lactis NCDO2118 and LL pXIES:pro-
chyB cultures were subjected to cell fractionation, and the protein
contents in both the cell (C) and cytoplasmic (T) fractions were
analyzed using western blot analysis.
High concentrations of prochymosin B were observed in the
cell fraction of LL pXIES:prochyB induced cultures, and the pres-
ence of prochymosin B attached to the cell envelope was evident.
This result could be due to the presence of inclusion bodies. In
the cytoplasmic fraction, a second band with an approximate
molecular weight of 35.6 kg/mol was also observed (Fig. 3),
which could represent degradation products. The detected poly-
peptides were chymosin specific as they were not detected in con-
trol L. lactis NCDO2118 cells and were recognized by specific
anti-chymosin antibodies.
Cloning active chymosin genes using the XIES system
Two new L. lactis strains producing the active forms of chy-
mosin A and B were also constructed in an attempt to improve
protein secretion efficiency. The ability of L. lactis to secrete the
different forms of mature chymosin (chymosin A or B) was eval-
uated. The chymosin B ORF was PCR-amplified from the
pBSIISK:prochyB vector using the chyB F and chyB R primers
(Table 2), and the chymosin A ORF was obtained by site-
directed mutagenesis of the chymosin B sequence using overlap
Figure 1. Structure and length of prochymosin and chymosin.
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extension PCR (Fig. 4) with the chyB F, chyB R, chyA mut F, and
chyA mut R primers (Table 2).
To obtain vectors that were able to target chymosin A and B
to the extracellular medium of L. lactis, the same procedure
adopted to construct pXYSEC:prochyB was performed resulting
in the pXYSEC:chyA and pXYSEC:chyB expression vectors. The
pXYSEC:chyA (Fig. 5A) and pXYSEC:chyB (Fig. 5B) vectors
were constructed by ligating the NsiI-EcoRV-digested pXIES
vector with the NsiI-EcoRV-digested chymosin A and B PCR
products, respectively. The construction of these expression plas-
mids was confirmed via enzymatic digestion and DNA sequenc-
ing. The plasmids were initially transformed into E. coli TOP 10
cells and then into L. lactis NCDO2118 cells, resulting in the LL
pXIES:chyA and LL pXIES:chyB recombinant strains.
Chymosin A and B were produced by L. lactis but remain
in the cells
The recombinant strains (LL pXIES:chyA and LL pXIES:chyB)
were constructed in an attempt to obtain efficiently secreted chy-
mosin in its active form. Once again, as with the LL pXIES:pro-
chyB strain, the secretion of the chymosin proteins was not
observed.
Proteins extracted from the induced LL pXIES:chyA and LL
pXIES:chyB cultures were analyzed using western blotting to eval-
uate whether these strains were able to produce active chymosin
and target it to the extracellular medium. Polypeptides of 39 kg.
mol¡1 were observed in the cell fractions (C), corresponding to
mature chymosin A or B fused to SPUsp45 (Fig. 5C and D), but
no proteins were observed in the supernatant fractions (S). These
results showed that direct expression of chymosin A and B by the
L. lactis XIES system is limited to the cell fraction as no secretion
was observed in the extracellular medium.
L. lactis producing chymosin A and B strains do not show
clotting activity
Clotting activity was evaluated using solubilized products of
the constructed L. lactis recombinant strains (LL pXIES:prochyB,
LL pXIES:chyA, and LL pXIES:chyB). To develop a simple and
sensitive assay to determine milk-clotting activity, a microtiter
plate platform was used. No milk-clotting activity was observed
in the recombinant strains or in L. lactis NCDO2118 (negative
Table 1. Bacterial strains and plasmids used in this work
Strain and/or plasmid Relevant characteristics Source
Bacterial strains
E. coli TOP10 (F¡w80dlacZDM15 D(lacZYA- argF)U169 endA1 recA1 hsdR17(rk- mkC) deoR thi-1 supE44 l¡ gyrA96 relA1) InvitrogenTM
L. lactis NCDO2118 L. lactis subsp. lactis (vegetable strain, plasmid free) Collection straina
LL pXIES:prochyB L. lactis NCDO2118 strain harboring pXYSEC:prochy B This work
LL pXIES:chyA L. lactis NCDO2118 strain harboring pXYSEC:chy A This work
LL pXIES:chyB L. lactis NCDO2118 strain harboring pXYSEC:chy B This work
Plasmids
pBSIISK:prochy B pBluescript II SK (Ampr/pUC ORI) cloning vector carrying prochymosin B gene with lactococcal codon usage Epoch Biolabs Inc
pXYSEC:Nuc pWV01/Cmr; expression vector containing the fusion rbsUsp45::spUsp45::nucB, under the control of PxylT Miyoshi and cols., 2004
pXYSEC:prochy B pXYSEC expression vector carrying prochymosin B gene with lactococcal codon usage This work
pXYSEC:chy A pXYSEC expression vector carrying chymosin A gene (obtained by mutagenesis) with lactococcal codon
usage
This work
pXYSEC:chy B pXYSEC expression vector carrying chymosin B gene with lactococcal codon usage This work
aDepartment of General Biology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG-ICB), Brazil
Table 2. Mutagenic and ﬂanking primers used to clone the chymosin genes
into expression vectors
Primers Sequence (50-30)b
Restriction
enzyme site
prochyB F GATGCATACTGAAATTACTCGAATTC NsiI
prochyB R GGATATCTTAGATGGCCTTGGCAAG EcoRV
chyB F TCGATGCATCA GGTGAGGTTGCAAGTGTTCCTC NsiI
chyB R GGAATTCTTAGATGGCCTTGGCAAGTCC EcoRI
chyA mut F GCAACACAAATCAATATGACgaatttgacatagattgtgac -
chyA mut R GTCATATTGATTTTGTGTTGCTCCAATAG -
bNucleotide substitution is shown in boldface; Underlined nucleotides indi-
cate the cloning site.
Figure 2. (A) Schematic representation of the plasmid constructed for
prochymosin production in L. lactis. For details about the plasmid con-
struction, see the text and Table 1. PxylT: xylose-inducible promoter;
RBSUsp45: ribosome binding site of the Usp45 gene; spUsp45: DNA
sequence encoding the signal peptide of the Usp45 gene; prochymosin
B: Bos taurus precursor chymosin B coding sequence based on lactococ-
cal codon usage. Plasmid constructed for prochymosin production with
secreted addressing (not to scale) (B) Immunodetection of recombinant
prochymosin produced by L. lactis. Analysis of proteins extracted from
the cell fraction using polyclonal anti-chymosin antibodies. Lanes 1 and
2: non-induced and induced LL pXIES:prochyB cultures, respectively; lane
3: commercial bovine chymosin (Sigma). d: prochymosin fused with the
lactococcal Usp45 signal peptide (SPusp45) (approximately 43 kg.mol
¡1).
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control), even after increasing the incubation time of the cultures
from 15 min to 2 h (data not shown).
Discussion
Genetically modified microorganisms have been produced
that can yield large quantities of pure chymosin (identical to ani-
mal chymosin) at very low cost. In this work, we proposed the
use of the L. lactis NCDO2118 strain, which can easily express
and control heterologous protein secretion using the XIES sys-
tem, as a new alternative for the production of chymosin as it
represents a safe strategy in cheese manufacturing. The XIES
expression system represents an interesting genetic tool for
obtaining biomolecules with pharmaceutical, medical or indus-
trial relevance.15,16
Here, for the first time, three different strains of L. lactis were
constructed for the production of the different forms of chymo-
sin, prochymosin B (precursor form) and chymosin A and B
(active forms). These results show that the three chymosin forms
can be expressed normally by the L. lactis XIES system but cannot
be secreted. They remain stacked in the cell fraction and present
no biological activity.
The LL pXIES:prochyB strain clearly produced the chymosin
precursor, which was detected in the cell envelope. No secretion
or clotting activity was observed using this strain. Similar results
were obtained with the L. lactis strains that produced chymosin A
and B (LL pXIES:chyA and LL pXIES:chyB, respectively). Consid-
ering that protein secretion in L. lactis occurs through a Sec-
dependent pathway, which has been used to produce and success-
fully secrete different heterologous proteins, our results suggest
that the transport of prochymosin B and chymosin A and B, via
this Sec pathway, could be impaired. It is known that recombi-
nant expression can be limited in L. lactis because expression of
the target proteins can be subject to inadequate stability and/or
solubility, leading to improper protein folding, inclusion body
formation, protein degradation17,18 and/or can be related to the
inefficiency of the secretion process.8 Thus, it is possible that a
post-translational process, such as insoluble aggregate formation,
could be limiting chymosin secretion. This represents a bottle-
neck in the production of soluble proteins that are intrinsically
associated with bacterial cell machinery conditions.
The secretion of prochymosin is important for obtaining the
activated protein; nevertheless, it seems that recombinant pro-
duction of this precursor is limited by its failure to form disulfide
bonds characterizing the formation of an insoluble cytoplasmic
prochymosin. Prochymosin is an extremely hydrophobic protein
that has been produced in E. coli, B. subtilis and yeast (cyto-
plasmic production) in its insoluble form, and, to become active,
the protein had to undergo a denaturing and refolding process.7,8
The molecular alteration of prochymosin is not able to signifi-
cantly change its hydrophobic nature because even deletion of
more than 70% of the protein-coding sequence was unable to
prevent significant accumulation of the insoluble protein.19 An
alternative to overcoming prochymosin aggregation and to
enhance its solubility, biological activity, and secretion is to fuse
the prochymosin B coding sequence to other DNA sequences.20
In Proteus mirabilis, the coding sequence was fused to exotoxin
type A streptococcal pyrogenic (Sep-A) with the promoter, RBS,
and signal peptide of Sep-A. Bovine prochymosin was secreted
into the extracellular medium, converted to its active form by
autocatalytic process and was capable of coagulating milk.21 L.
lactis strains harboring plasmids with different fusion cassettes for
expression and/or secretion of prochymosin and proteinase-pro-
chymosin fusion proteins produced intra and extracellular pro-
chymosin. The ratio of secreted to intracellular prochymosin
increased with increasing length of the fusion cassette. This
Figure 3. Immunodetection to determine the cellular localization of
recombinant prochymosin B using polyclonal anti-chymosin antibodies.
Analysis of proteins extracted from the cell (C) and cytoplasmic (T) frac-
tions of the L. lactis NCDO2118 (wild type) and LL pXIES:prochyB strains
from induced culture samples. Lane 1: molecular weight standard
(BenchMark Protein Ladder; Invitrogen); lanes 2 and 3: T and C protein
fractions of L. lactis NCDO2118, respectively; lanes 4 and 5: T and C pro-
tein fractions of LL pXIES:prochyB, respectively. e: prochymosin fused
with the signal peptide of lactococcal Usp45 (SPusp45) (approximately
43 kg.mol¡1).
Figure 4. Schematic representation of the overlap extension PCR
method used.
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represents a promising strategy for use in L. lactis because the
fusion of the prochymosin sequence (or even chymosin A and B)
with leader sequences from other lactococci gene coding
sequence, could result in its secretion by L. lactis.22 Furthermore,
the insertion of a 9-residue synthetic propeptide LEISSTCDA
could enhance the efficiency of chymosin secretion by L. lactis.12
In this work, the mature forms of the chymosin genes were
cloned and expressed in L. lactis for the first time. The expression
of mature chymosin A and B by recombinant L. lactis strains (LL
pXIES:chyA and LL pXIES:chyB, respectively) was successfully
observed, but secretion and clotting activity were not detected.
Few studies describe the cloning and expression of chymosin in
its active form. However, this product cannot be easily obtained,
as was shown in a B. subtilis clone that was genetically modified
to produce mature chymosin. Despite confirmation of the clones,
they were not able to produce the protein.8 The inefficiency in
producing mature chymosin and presenting its milk-clotting
activity has been observed in recombinant Saccharomyces cerevi-
siae strains. Furthermore, it has also been observed that some chy-
mosin polypeptides are associated with the cell wall, and because
no chymosin polypeptides are detected in the soluble fractions,
this suggested that the synthesized protein could be rapidly asso-
ciated with cell wall debris or was in an insoluble form.23 In E.
coli, direct expression of the chymosin gene would be expected to
lead to production of chymosin containing an additional methio-
nine residue at the NH2 terminus which can cause deleterious
effects on the production of active chymosin. There was also the
possibility that an NH2-terminal methionine would modify the
activity or tertiary structure of the enzyme, proofing that active
chymosin expression in E. coli presented disadvantages.7
Figure 5. (A, B) Schematic representation of the plasmids constructed for chymosin A and B production in L. lactis. For details about plasmid construc-
tion, see the text and Table 1. PxylT: xylose-inducible promoter; rbsUsp45: ribosome binding site of the Usp45 gene; spUsp45: DNA sequence encoding the
signal peptide of Usp45 gene; chymosin A: Bos taurus active chymosin A coding sequence obtained by site-directed mutagenesis of chymosin B; chymo-
sin B: Bos taurus active chymosin B coding sequence based on lactococcal codon usage (A) plasmid constructed for chymosin A production with secreted
addressing. (B) plasmid constructed for chymosin B production with secreted addressing (not to scale) (C, D) Immunodetection of recombinant chymo-
sin A and B produced by L. lactis strains. Analysis of proteins extracted from the cell fraction using polyclonal anti-chymosin antibodies. (C) Lanes 1 and
2: LL pXIES:chyA non-induced and induced culture samples, respectively; lane 3: commercial bovine chymosin (Sigma). (D) Lanes 1 and 2: LL pXIES:chyB
non-induced and induced culture samples, respectively; (lane 3) commercial bovine chymosin (Sigma). g and h: chymosin A and B fused with the signal
peptide of lactococcal Usp45 (SPusp45) (approximately 38.7 kg.mol
¡1), respectively.
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Even after protein solubilization, the recombinant L. lactis
strains lacked clotting activity. It is possible that the low produc-
tion of heterologous protein could be responsible for the lack of
clotting activity. To improve the production of the heterologous
protein, different versions of chymosin were cloned into plasmids
with different characteristics (promoter, RBS, ATG, fusion pro-
tein). Low production of prochymosin in B. subtilis was signifi-
cantly increased (10£) by coupling the lpp gene coding
sequence.8,24 The protein synthesis efficiency is based on a two-
sequences arrangement and it relies on translational coupling for
which the second prokaryotic ribosome-binding site sequence,
RBS, is dependent of the first sequence upstream of it.8
The improvement of expression systems has facilitated obtain-
ing recombinant chymosin mostly from genetically modified
fungi. Pichia pastors has been successfully used to produce chy-
mosin from different sources using different promoters and
expression systems.25-27
Considering these results, new expression system tools are
being developed to improve the secretion of chymosin by the L.
lactis NCDO2118 strain.
Conclusions
This work is part of an ongoing project that aims to produce
enzymes or antigens in L. lactis that are beneficial to animal and/
or human health. Here, we have described the construction of
recombinant lactococcal strains that produce three derivates of
calf chymosin, the most important enzyme in cheese production
with high specificity for k-casein.28
The three constructed recombinant strains were able to pro-
duce a stable form of chymosin but were unable to export it to
the extracellular environment. The failure of secretion and the
presence of proteins stacked in the cellular fraction is most likely
the result of an alteration in protein folding, which could
improve production, secretion and translocation processes. Thus,
the development of other strategies, which could facilitate the
downstream processing and recovery of this protein, will be nec-
essary to achieve both production and targeting of chymosin in
L. lactis.
Materials and Methods
Bacterial strains, plasmids, and growth conditions
Bacterial strains and plasmids used in this study are listed in
Table 1. Escherichia (E.) coli TOP10 cells were aerobically grown
in Luria-Bertani medium at 37C with agitation. L. lactis
NCDO2118 cells were grown in M17 medium supplemented
with 0.5% (w/v) glucose (GM17) or 1% (w/v) xylose (XM17;
when induced) at 30C without agitation. When required, media
were supplemented with chloramphenicol (Cm; 10 mg mL ¡1).
DNA manipulations
Unless otherwise indicated, DNA manipulation techniques
were performed according to standard protocols. Plasmid DNA
was isolated from E. coli and L. lactis, as previously described.29,30
PCR amplifications were performed using Platinum Pfx DNA
Polymerase (InvitrogenTM). DNA fragments were isolated from
the agarose gels and purified using the GFXTM PCR DNA and
Gel Band Purification system (GE Healthcare). DNA restriction
and modification enzymes were used as recommended by the
suppliers. The integrity of all cloned ORFs was confirmed by
sequencing performed on double-stranded plasmid DNA using
the dideoxy chain termination method.31
Construction of the synthetic prochymosin B ORF
The prochymosin B ORF (Bos taurus; NM_180994.1) was
synthesized with all codons optimized for expression in L. lac-
tis32,33 and cloned into the pBluescript II SK (C/¡) vector by
Epoch Biolabs Inc The resulting vector (pBSIISK:prochyB), har-
boring the synthetic prochymosin B, was used as a template to
obtain the chymosin A and B ORFs (Fig. 1).
Primer design
All primers used in this work were designed using the Vector
NTI 10 software (Invitrogen) and are shown in Table 2. The pri-
mers were designed based on the synthetic prochymosin B and
contained the appropriate restriction sites for subsequent cloning
steps.
Isolation of the prochymosin B, chymosin A, and chymosin
B ORFs
The prochymosin B and chymosin B ORFs were PCR-ampli-
fied from the pBSIISK:prochyB vector using the prochyB F and
prochyB R or chyB F and chyB R primers, respectively.
The chymosin A ORF was obtained by site-directed mutagen-
esis of the chymosin B coding sequence (Fig. 4). For site-directed
mutagenesis, four primers were used: (1) a pair of primers flank-
ing the chymosin B ORF (chyB F and chyB R) and (2) a pair of
mutagenic primers with an average 21-bp overlap between adja-
cent fragments (chyA mut F and chyA mut R). The mutation site
was located in these mutagenic primer sequences.
Site-directed mutagenesis was performed using the overlap
extension-PCR method that consists of a three-step PCR proce-
dure.34 Briefly, two simultaneous PCR reactions were performed
in the first step. One reaction was performed with the chyB F and
chyA mut R primers and the other reaction was performed with
the chyA mut F and chyB R primers.
To obtain the full-length mutated fragment coding chymosin
A, the products from both PCR reactions were mixed (approxi-
mately 60 ng each) and used as templates for a subsequent over-
lap extension-PCR reaction. This PCR was performed without
adding primers and using the same conditions previously
described. A final PCR reaction was performed using the full-
length DNA product previously obtained and the pair of chymo-
sin B primers (chyB F and chyB R). The amplified products were
gel purified and digested with NsiI and EcoRI restriction enzymes
(Table 2) before being cloned into the pXYSEC expression
vector.
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Construction of L. lactis strains targeting prochymosin B,
chymosin A and chymosin B to the extracellular medium
The PCR fragment containing the prochymosin B ORF was
purified, digested with NsiI and EcoRV and cloned directly into
the NsiI and EcoRV-digested pXYSEC expression vector, result-
ing in the pXYSEC:prochyB vector. The same procedure was
adopted to clone the chymosin A and B ORFs, resulting in the
pXYSEC:chyA and pXYSEC:chyB vectors, respectively. The vec-
tors were first transformed into E. coli TOP10 cells and then
transferred after purification to L. lactis NCDO2118 cells by
electroporation. The final lactococcal strains were as follows: (i)
L. lactis (pXYSEC:prochyB), hereafter called LL(pXYSEC:pro-
chyB); (ii) L. lactis (pXYSEC:chyA), hereafter called LL(pXYSEC:
chyA); and (iii) L. lactis (pXYSEC:chyB), hereafter called LL
(pXYSEC:chyB).
Xylose induction conditions
The wild type L. lactis NCDO2118 strains or the recombi-
nant strains (harboring pXYSEC:prochyB, pXYSEC:chyA or
pXYSEC:chyB) were grown overnight in 5 mL of GM17 media.
The overnight culture was diluted 1:10.000 in 10 mL of fresh
XM17 media to induce the expression of the prochymosin and
chymosins ORFs. Incubation at 30C was continued until the
cultures reached an optical density of 2.0 at 600 nm (OD600),
before performing protein extractions.
Protein extraction
Protein extractions of the supernatant, cell, and cytoplasmic
fractions were performed as previously described.17 Briefly, 2 mL
of exponential-phase cultures [optical density at 600 nm
(OD600), 1.5 to 2.0] was centrifuged at 4
C for 10 min at
17,500 £ g. The supernatants and the cell pellets were processed
separately. The supernatants were filtered through 0.2 mm filters
(low protein retention; Millipore) to remove the bacteria and
proteins from 1.5 mL of the filtrate were precipitated with
100 mL of ice-cold 100% (w/v) trichloroacetic acid. The mixture
was kept on ice for 60 min and then centrifuged at 4C for
15 min at 17 500 £ g. The resulting pellet was dissolved in
75 mL per OD600 unit of the 50 £ 10¡3 mol L¡1 of NaOH.
The cell fraction was resuspended in 100 mL of TE-Lys buffer (1
£ 10¡3 mol L¡1 EDTA, 50 £ 10¡3 mol L¡1 TRIS-HCl [pH
7.5], lysozyme [10 mg mL¡1]), homogenized, incubated in a
water bath for 30 min at 37C and then 33 mL of 20% (w/v)
sodium dodecyl sulfate (SDS) per OD600 unit of the original cul-
ture was added.
Proteins of the cytoplasmic fraction were obtained from the
pellet and treated with TE-Lys solution in the same manner as
the cell fraction. However, the samples were centrifuged for
10 min at 17 500 x g at 4C. The supernatants were filtered
(0.22 mm) and underwent the same treatment as the supernatant
fraction, described above.
Polyclonal anti-chymosin production
BALB/c mice (5 to 6 wk old) were obtained from the Federal
University of Minas Gerais (UFMG, Brazil). The animals were
immunized with 20 mg of purified chymosin (Sigma). Three
doses were administered subcutaneously at intervals of 15 d.
Freund’s complete adjuvant was administered with the first dose,
and Freund’s incomplete adjuvant was administered with subse-
quent doses. Samples were collected on days 0, 14, 28, and 42
after the first dose. The first samples were taken from the retro-
orbital plexus, and the last samples were taken from the heart.
The humoral immune response was evaluated by an indirect
ELISA assay (enzyme-linked immunosorbent assay).
Western blot analysis
Equal volumes of 2X loading buffer were added to all protein
samples. Protein extracts were subjected to SDS-PAGE (12%
acrylamide) and western blotting using anti-chymosin antibodies,
as previously described.21 Immunodetection was performed using
Western Breeze Chromgenic Western Blot Immunodetection (Invi-
trogen), as recommended by the manufacturers.
Chymosin milk-clotting activity assay
The three recombinant L. lactis strains, producing prochymo-
sin B, chymosin A or chymosin B, were analyzed for clotting
activity. Prochymosin was converted to catalytically active chy-
mosin by acidification and/or neutralization (activation) immedi-
ately prior to the assay, first by acidification to pH 2.0 for 15 min
at room temperature and then by adjusting the pH to 6.3; incu-
bation was continued for 1 h. Non-induced strains and the
L. lactis NCDO2118 wild type strain were used as negative
controls.
For solubilization of aggregate chymosin, we used the Marston
et al. (1984) protocol.35 The extract was concentrated using
Amicon Ultra (10.000MW cut-off) centrifugal filters. Twenty-five
microliters of each sample were used to evaluate chymosin milk-clot-
ting activity using a previously described technique by Emtage et al.
(1983), with incubation times of 15 min or 2 h.7
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